PMN — ProMIS Neurosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374339 ·
Last close
$11.27
Market Cap
$101.07M
52W High
$27.40
52W Low
$6.27
ADV30
38,763
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,266,399 | -11,729,656 | 56,693,933 | 53,429,280 | 7,294,999 |
| Mar 2026 | 0 | — | -8,644,895 | -8,244,372 | 67,411,571 | 63,814,345 | 6,693,999 |
| Dec 2025 | 0 | — | -10,772,119 | -10,674,088 | 9,182,421 | 6,116,556 | 10,441,013 |
| Sep 2025 | 0 | — | -11,750,432 | -11,580,126 | 21,458,147 | 15,399,165 | 12,270,792 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,575,233
Investing CF
—
Financing CF
$91,025,979
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-23.79
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-138,650,592
Inventory
—
Receivables
$238,329
ST Investments
$33,753
EBIT TTM
$-41,016,138
Pretax Income TTM
$-40,615,615
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -40,167,308 | -39,719,147 | 9,182,421 | 10,441,013 | -1,258,592 | -28,118,579 |
| Dec 2024 | 0 | -16,827,478 | 2,778,873 | 18,911,456 | 2,423,280 | 16,488,176 | -27,182,095 |
| Dec 2023 | 0 | -14,262,733 | -13,212,482 | 13,619,145 | 9,865,849 | 3,753,296 | -10,843,676 |
| Dec 2022 | 0 | -23,379,912 | -18,062,263 | 6,924,646 | 8,272,418 | -1,347,772 | -17,033,883 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RFL | Rafael Holdings, Inc. | $99.35M | $1.94 | — |
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
| MIST | Milestone Pharmaceuticals Inc. | $98.10M | $0.79 | — |
| PLYX | Polaryx Therapeutics, Inc. | $104.18M | $2.09 | — |
| ANIX | Anixa Biosciences Inc | $96.64M | $2.78 | — |
News headlines (Yahoo Finance, 1h cache)
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
2026-09-01 12:00 · Yahoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
2026-08-14 05:02 · Yahoo
Promis Neurosciences Q2 Earnings Call Highlights
2026-08-14 02:04 · Yahoo
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
2026-08-13 20:00 · Yahoo
Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
2026-07-28 18:04 · Yahoo
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
2026-07-27 20:00 · Yahoo
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
2026-07-14 06:30 · Yahoo
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
2026-06-12 16:00 · Yahoo
ProMIS Neurosciences to Participate in Upcoming Conferences in June
2026-05-28 14:13 · Yahoo
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-13 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.